[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5b23eab5-3fc3-4d0b-872b-b13059602b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05567055","created_at":"2022-10-05T13:56:16.483Z","updated_at":"2025-02-25T15:54:39.244Z","phase":"Phase 2","brief_title":"Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations","source_id_and_acronym":"NCT05567055","lead_sponsor":"Timothy Burns, MD, PHD","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-06-17"},{"id":"fe03cda1-1670-4c2f-aa16-3697bbbeabf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04575025","created_at":"2021-01-27T19:00:57.694Z","updated_at":"2024-07-02T16:34:25.927Z","phase":"","brief_title":"Special Drug Use-results Surveillance of Tabrecta Tablets","source_id_and_acronym":"NCT04575025","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"4a5cc8d4-4988-48bd-a23f-3af70e820203","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05642572","created_at":"2022-12-08T14:57:35.488Z","updated_at":"2024-07-02T16:34:27.426Z","phase":"Phase 2","brief_title":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05642572 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-11"},{"id":"e3cb8ff7-aee3-44ab-9a12-a32ca7fbea3e","acronym":"GeoMETry-C","url":"https://clinicaltrials.gov/study/NCT04677595","created_at":"2021-01-19T20:46:00.824Z","updated_at":"2024-07-02T16:35:04.004Z","phase":"Phase 2","brief_title":"Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","source_id_and_acronym":"NCT04677595 - GeoMETry-C","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR wild-type • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/17/2021","start_date":" 05/17/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-14"},{"id":"677edd33-9a1c-430c-98a8-3977cf1e241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110196","created_at":"2021-11-05T12:53:26.883Z","updated_at":"2024-07-02T16:35:07.074Z","phase":"Phase 4","brief_title":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","source_id_and_acronym":"NCT05110196","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK • MET","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation","tags":["EGFR • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2022","start_date":" 09/03/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-04-29"},{"id":"39c77db3-f6b0-47a8-808d-f2f9933c2f27","acronym":"GEOMETRY mono-1","url":"https://clinicaltrials.gov/study/NCT02414139","created_at":"2021-01-17T17:12:03.114Z","updated_at":"2024-07-02T16:35:13.913Z","phase":"Phase 2","brief_title":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","source_id_and_acronym":"NCT02414139 - GEOMETRY mono-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 373","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2024-03-20"},{"id":"9fa62c00-1280-4ec0-8c98-1fa195a56422","acronym":"","url":"https://clinicaltrials.gov/study/NCT04741789","created_at":"2021-09-08T17:53:30.588Z","updated_at":"2024-07-02T16:35:20.221Z","phase":"","brief_title":"Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04741789","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-08"},{"id":"cee602fb-6d33-45f6-b2f6-248a2d8fdf61","acronym":"PLATforM","url":"https://clinicaltrials.gov/study/NCT03484923","created_at":"2021-01-18T17:10:00.250Z","updated_at":"2024-07-02T16:35:22.981Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03484923 - PLATforM","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" LAG3","pipe":" | ","alterations":" BRAF wild-type","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Tabrecta (capmatinib) • spartalizumab (PDR001) • Ilaris (canakinumab) • ieramilimab (LAG525)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-01-18"},{"id":"a563cbb8-fb97-4cc4-bda2-54204ed92285","acronym":"Geometry-N","url":"https://clinicaltrials.gov/study/NCT04926831","created_at":"2021-06-15T17:53:18.896Z","updated_at":"2024-07-02T16:35:26.249Z","phase":"Phase 2","brief_title":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC","source_id_and_acronym":"NCT04926831 - Geometry-N","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 08/10/2022","start_date":" 08/10/2022","primary_txt":" Primary completion: 08/06/2026","primary_completion_date":" 08/06/2026","study_txt":" Completion: 08/06/2026","study_completion_date":" 08/06/2026","last_update_posted":"2023-12-14"},{"id":"5f658d50-b285-4718-a0f3-8b13fbe2e2a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02386826","created_at":"2021-01-18T11:22:35.901Z","updated_at":"2025-02-25T15:42:18.866Z","phase":"Phase 1","brief_title":"INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme","source_id_and_acronym":"NCT02386826","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 09/22/2015","start_date":" 09/22/2015","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 08/23/2023","study_completion_date":" 08/23/2023","last_update_posted":"2023-09-21"},{"id":"ac5acaad-e81c-452a-8add-e324e99252a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02795429","created_at":"2021-06-15T00:55:17.811Z","updated_at":"2024-07-02T16:35:44.225Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC","source_id_and_acronym":"NCT02795429","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2023-06-30"},{"id":"ad61c6e7-badf-4c88-9e63-73015477a093","acronym":"RECAP","url":"https://clinicaltrials.gov/study/NCT05796726","created_at":"2023-04-03T14:03:14.268Z","updated_at":"2024-07-02T16:35:51.546Z","phase":"","brief_title":"Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations","source_id_and_acronym":"NCT05796726 - RECAP","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 12/10/2021","start_date":" 12/10/2021","primary_txt":" Primary completion: 03/22/2022","primary_completion_date":" 03/22/2022","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-04-03"},{"id":"8b39fe27-0ffb-430b-b908-c4776bc8d456","acronym":"METIMGAST","url":"https://clinicaltrials.gov/study/NCT05135845","created_at":"2021-11-26T14:53:40.144Z","updated_at":"2024-07-02T16:35:56.487Z","phase":"Phase 2","brief_title":"Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma","source_id_and_acronym":"NCT05135845 - METIMGAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" HER-2 positive • MET amplification","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Suspended","enrollment":" Enrollment 90","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-02-03"},{"id":"1d0ee4ca-bbf9-47c0-82fc-b76e0cd9df7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05675683","created_at":"2023-01-09T14:58:49.621Z","updated_at":"2024-07-02T16:35:57.971Z","phase":"","brief_title":"Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib","source_id_and_acronym":"NCT05675683","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2023-01-09"},{"id":"2e601dcd-8f90-40ff-a997-b2a5184ade01","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750215","created_at":"2021-01-18T13:28:23.050Z","updated_at":"2025-02-25T15:53:17.763Z","phase":"Phase 2","brief_title":"A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor","source_id_and_acronym":"NCT02750215","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • MET exon 14 mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET exon 14 mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-03-14"},{"id":"db4851dd-1f9c-4dc1-b478-d957077c8416","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647488","created_at":"2021-01-18T17:54:15.660Z","updated_at":"2024-07-02T16:36:18.117Z","phase":"Phase 2","brief_title":"Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03647488","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/26/2018","start_date":" 12/26/2018","primary_txt":" Primary completion: 09/07/2020","primary_completion_date":" 09/07/2020","study_txt":" Completion: 09/07/2020","study_completion_date":" 09/07/2020","last_update_posted":"2022-01-24"},{"id":"e02c420f-a139-4835-ba97-92535de111e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911507","created_at":"2021-01-18T08:37:01.568Z","updated_at":"2025-02-25T15:40:58.472Z","phase":"Phase 1","brief_title":"INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01911507","lead_sponsor":"University of California, Davis","biomarkers":" EGFR • KRAS • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • KRAS wild-type • EGFR L861Q • RAS wild-type • EGFR G719X • MET expression","tags":["EGFR • KRAS • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • KRAS wild-type • EGFR L861Q • RAS wild-type • EGFR G719X • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-10-13"},{"id":"98b338ca-7e46-4a04-b381-f7878ee43d62","acronym":"CINC280X2202","url":"https://clinicaltrials.gov/study/NCT01610336","created_at":"2021-01-18T06:53:42.388Z","updated_at":"2024-07-02T16:36:32.157Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","source_id_and_acronym":"NCT01610336 - CINC280X2202","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 04/05/2012","start_date":" 04/05/2012","primary_txt":" Primary completion: 06/10/2016","primary_completion_date":" 06/10/2016","study_txt":" Completion: 05/27/2020","study_completion_date":" 05/27/2020","last_update_posted":"2021-04-08"},{"id":"d3e4bc84-d494-4f6e-b098-856be6a86d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324479","created_at":"2021-01-18T05:23:36.158Z","updated_at":"2024-07-02T16:36:37.116Z","phase":"Phase 1","brief_title":"Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors","source_id_and_acronym":"NCT01324479","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" EGFR wild-type • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 07/04/2017","primary_completion_date":" 07/04/2017","study_txt":" Completion: 07/04/2017","study_completion_date":" 07/04/2017","last_update_posted":"2020-12-19"},{"id":"eb98d175-5a34-46f6-845c-f629ab6302c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02276027","created_at":"2021-01-18T10:42:42.037Z","updated_at":"2024-07-02T16:36:37.310Z","phase":"Phase 2","brief_title":"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02276027","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Mektovi (binimetinib) • Zykadia (ceritinib) • Tabrecta (capmatinib) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/20/2015","start_date":" 01/20/2015","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2020-12-16"},{"id":"0a94fe0d-06f9-4f68-bbfc-471016e0ccc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04460729","created_at":"2021-01-18T21:26:50.446Z","updated_at":"2024-07-02T16:36:37.846Z","phase":"Phase 2","brief_title":"A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases","source_id_and_acronym":"NCT04460729","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET mutation • EGFR rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET mutation • EGFR rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2020-12-03"},{"id":"c5ac583b-dc41-48f2-91f9-b31520f11620","acronym":"","url":"https://clinicaltrials.gov/study/NCT03693339","created_at":"2021-01-27T18:57:38.673Z","updated_at":"2024-07-02T16:37:06.450Z","phase":"Phase 2","brief_title":"Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation","source_id_and_acronym":"NCT03693339","lead_sponsor":"Asan Medical Center","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 27","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2018-10-03"},{"id":"0ef3ec4e-02de-48f7-b3c8-5c306f1b5b30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03240393","created_at":"2021-01-18T16:00:42.617Z","updated_at":"2024-07-02T16:37:08.580Z","phase":"Phase 2","brief_title":"Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03240393","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/31/2018","start_date":" 07/31/2018","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 10/26/2021","study_completion_date":" 10/26/2021","last_update_posted":"2018-07-26"}]